{
    "nctId": "NCT04581967",
    "briefTitle": "Study of CYP2C19 and ALDH3A1 Polymorphisms in Breast Cancer Patients",
    "officialTitle": "Pharmacogenetic Risk Factors of Doxorubicin-Cyclophosphamide Chemotherapy Related Toxicities in Breast Cancer Patients",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer Patients",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "The frequency of the genetic polymorphisms of CYP2C19 in breast cancer patients",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Confirmed diagnosis of breast cancer.\n2. Age ranging from 18 to 75 years old female.\n3. Patients will take Doxorubicin-Cyclophosphamide regimen as chemotherapy treatment.\n\nExclusion Criteria:\n\n1. Any other malignancy.\n2. Previous treatment for metastatic disease.\n3. Pregnancy or breastfeeding female.\n4. Inadequate bone marrow and cardiac function.\n5. Serious or uncontrolled medical conditions.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}